PHPeter Gerrit Johannes ter Horst

Peter Gerrit Johannes ter Horst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Gerrit Johannes ter Horst has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medication, age and abstinence days associated with low semen quality: A cross-sectional study in more than 7000 men visiting the centre for reproductive medicine

    by P.G.J. ter Horst, M.A. Edens, D. Den Besten-Bertholee, L.W. Mulder, M.H.J.M. Curfs

    Medication can affect semen quality by decreasing ejaculate volume, sperm concentration, or decreased sperm motility and sperm function in general. We performed a retrospective explorative cross-sectional study on any medication use and semen quality in our fertility clinic in men older than 18 years with a recorded semen analysis. Men were categorized based on medication use, i.e., any type, and no medication use. Exclusion criteria were incomplete semen analysis, azoospermia, a semen analysis after vasectomy, and days of abstinence less than 2 or more than 7 days before semen collection. The primary outcome was the composite endpoint of low semen quality (LSQ) according to the WHO. In total 722 men with medication and 6716 men without medication were included in the study. At the ATC-7 level (individual drug ATC-code), univariate (borderline) statistically significant associations using a cut-off of p < 0.100 were found for metformin (A10BA02), metoprolol (C07AB02) and lisinopril (C09AA03), which remained significant after adjustment for age and abstinence days. Our study is limited by the fact that information regarding exposure to information, as information was self-reported by patients. Also, the outcome, semen quality, was hindered by patients own collection. Even if a drug had logically been used for some time before semen sampling (e.g., medication for chronic disease), there was no way to determine whether that medication had been started before or after the occurrence of LSQ. Finally, medication and disease cannot be separated, hence it could not be determined whether the medication or the disease itself was associated with LSQ. Therefore, this study should be interpreted as a hypothesis-generating study.


  • A pilot study on in-utero exposure to psychotropic drugs: A comparison of pharmacological classes on neonatal and maternal outcomes

    by Elvera A. Damer, Demi van Kampen, Mireille A. Edens, Marieke A.C. Hemels, Bas S.W.A. Nij Bijvank, Peter G.J. ter Horst


  • Open Access

    The impact of pregnancy on the pharmacokinetics of antiseizure medications: A systematic review and meta-analysis of data from 674 pregnancies

    by Georgios Schoretsanitis, Kristina M. Deligiannidis, Nicholas Kasperk, Chiara Theresa Schmidt, Sarah Kittel-Schneider, Peter Ter Horst, Maya Berlin, Elkana Kohn, Eline M.P. Poels, Deepti Zutshi, et al.


  • Anidulafungin Levels in Breast Milk After Cessation of Treatment: A Case Report

    by Job F.H. Eijsink, André Wieringa, Marie-Therese L.M. Vries-Koenjer, Peter G.J. ter Horst

    Background: Anidulafungin has poor oral bioavailability, with hardly any available information on how it affects breast milk, oral absorption, or gastrointestinal side effects in the infant. Case Presentation: A 40-year-old woman who recently gave birth to a healthy infant was treated for a period of 14 days for a Candida glabrata with 100 mg anidulafungin once a day. The department of clinical pharmacy was consulted to provide advice on how long the patient had to wait after ceasing anidulafungin before it was safe to start breastfeeding, with regard to preventing possible side effects of the drug to the infant, such as diarrhea or cholestasis and increase in liver enzyme values. The advice of the hospital pharmacist was pragmatic: to start breastfeeding within 2 days after the medication was discontinued based on half-time. Results: Owing to this lack of information, we measured anidulafungin concentrations in breast milk and found low levels. Conclusion: We concluded that anidulafungin is detectable in breast milk until 32 hours after anidulafungin treatment was stopped, and that no side effects were observed by the infant.

  • Risks associated with antidepressants in patients with hypertension during pregnancy: a retrospective cohort study

    by Marlieke Oude Weernink, Elvera A. Damer, Mireille A. Edens, Bas S. W. A. Nij Bijvank, Marieke A. C. Hemels, Peter G. J. ter Horst

    Purpose In a cohort of pregnant women using antihypertensive drugs, we compared exposure to antidepressants versus no exposure and the possible association with birth weight, APGAR scores, NICU admission, and maternal admission to an obstetrical intensive care unit (OHC). It was hypothesized that pregnant women with hypertensive disorders using antidepressants are at greater risk of complications. Methods A retrospective cohort study in a general teaching hospital in Zwolle, in the Middle-Northern part of The Netherlands. Finally, 58 pregnancies in the exposed group and 273 pregnancies in the reference group met all inclusion and exclusion criteria. We compared the neonate’s birthweight between the exposed to antidepressants group and the reference group as the primary outcome. Secondary outcomes were the APGAR score at 1 and 5 min and obstetric high care (OHC) admission of the mother and neonatal intensive care unit (NICU) admission of the child. Results We found no differences in birth weight in neonates of mothers with hypertensive disorders and whether or not to use antidepressants. Besides a possible higher risk of admission to an OHC in women with hypertension-complicated pregnancies using antidepressants, we found no other maternal or neonatal risks in this population. Conclusion We found no additional maternal or neonatal risks of using antidepressants prescribed to women with hypertension disorders during pregnancy.


  • Open Access

    Risks associated with antidepressants in patients with hypertension during pregnancy: a retrospective cohort study

    by Marlieke Oude Weernink, Elvera Damer, Mireillie Edens, Bas Nij Bijvank, Marieke Hemels, Peter Ter Horst

    Objective In a cohort of pregnant women using antihypertensive drugs, we compared exposure to antidepressants versus no exposure and the possible association with birth weight, APGAR scores, NICU admission, and maternal admission to an obstetrical intensive care unit (OHC). It was hypothesized that pregnant women with hypertensive disorders using antidepressants are at greater risk of complications. Setting A retrospective cohort study in a general teaching hospital in Zwolle, in the Middle-Northern part of The Netherlands. Participants We selected 77 pregnancies eligible for the exposed group and 293 eligible for the reference group. Of those, we excluded patients because of twin pregnancy, stillbirth, patients who discontinued antidepressants during pregnancy, and termination of the pregnancy not related to hypertension or mental health problems during pregnancy. Finally, 58 pregnancies in the exposed group and 273 pregnancies in the reference group met all inclusion and exclusion criteria. Outcome We compared the neonate’s birthweight between the exposed to antidepressants group and the reference group as the primary outcome. Secondary outcomes were the APGAR score at 1 and 5 minutes and obstetric high care (OHC) admission of the mother and neonatal intensive care unit (NICU) admission of the child. Results We found no differences in birth weight in neonates of mothers with hypertensive disorders and whether or not to use antidepressants. Besides a possible higher risk of admission to an OHC in women with hypertension-complicated pregnancies using antidepressants, we found no other maternal or neonatal risks in this population. Conclusions We found no additional maternal or neonatal risks of using antidepressants prescribed to women with hypertension disorders during pregnancy.

  • Open Access

    Levetiracetam en zwangerschap: relatie tussen concentraties en aanvallen

    by Meike Schelhaas, Ilse Wegner, Mireille Edens, Elisabeth Wammes-Van der Heijden, Daniel Touw, Peter Ter Horst

    Optimale behandeling van epilepsie tijdens de zwangerschap is belangrijk voor zowel moeder als kind. De dosering van anti-aanvalsmedicatie moet soms worden aangepast vanwege een snellere eliminatie dan gebruikelijk. In een uitgebreide studie werd de daling van serumconcentraties van levetiracetam en de consequenties hiervan voor de aanvalsfrequentie onderzocht.

  • Maternal and neonatal outcomes after benzodiazepine and benzodiazepine agonist exposure during pregnancy in women with mental disorders

    by Hennique Knobbe, Elvera A. Damer, Mireille A. Edens, Bas S. W. A. Nij Bijvank, Marieke A. C. Hemels, Peter G. J. ter Horst

    Aims: To compare the gestational age of neonates in utero exposed to benzodiazepines (BDZs) with nonexposed controls. Secondary objectives were birth weight, presence of congenital malformations, APGAR score and the need for >3 months (prolonged) maternal psychiatric care.Methods: A retrospective cohort study of women and neonates from 2013 to 2021 with univariate and multivariable analysis to study the associations between BDZ exposure and gestational age compared to nonexposed women with mental health problems.Results: We found that BDZ exposure was not associated with a lower gestational age. We found that women in the exposed group had an increased risk of psychiatric care (adjusted odds ratio 2.58 [95% confidence interval 1.71–3.91], P < .001).Conclusion: We found that in utero BDZ exposure was not associated with a significantly lower gestational age of the neonates and was associated with prolonged psychiatric care of their mothers.


  • Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy

    by Meike Schelhaas, Ilse Wegner, Mireille Edens, Elisabeth Wammes-Van Der Heijden, Daniel Touw, Peter Ter Horst

    Background and Objectives: Pharmacologic treatment of epilepsy in pregnant women is balancing between risks for mother and for fetus. Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other anti-seizure medications (ASMs). Recent studies have shown decline of ASM concentrations during pregnancy because of physiologically-based pharmacokinetic changes. In this study, we established this decrease in LEV concentration during pregnancy. Additionally, we aimed at investigating the effect of the low LEV levels during pregnancy and develop a target value for the level during pregnancy. Methods: Pregnant patients using levetiracetam were studied in this retrospective cohort study. Blood samples were monthly collected through venous puncture or the dried blood spot method. ASM serum concentrations were determined at least six months prior to conception and for each month of pregnancy. Seizure frequency and ASM dosages during pregnancy were obtained from patient records. Patients were divided into two groups: a ‘seizure free’ and a ‘non-seizure free’ group which contained pregnancies in which mother had experienced an epileptic seizure more than twelve months and less than twelve months before pregnancy, respectively. Results: We found decreased concentration/dose ratios in 29 pregnancies throughout all months of pregnancy. In the non-seizure free group, it was found that low LEV concentrations were associated with seizure increase frequency (p=0.022). For this group the cut off-value with the highest sum of sensitivity and specificity was 0.466. Discussion: All in all, we recommend therapeutic drug monitoring for all pregnant patients on LEV as the concentrations of LEV significantly decrease throughout most months of pregnancy. However, this decrease in LEV concentration was only significantly correlated with seizure deterioration in patients who had a seizure in the year preceding the pregnancy . Therefore, we suggest more careful monitoring of non-seizure free patients as they are at higher risk for experiencing an increase of seizure frequency. For this group, we advise physicians to keep LEV concentration above 65% of the preconceptional concentration. For seizure free patients we recommend a LEV threshold value of approximately 46% of the preconceptional concentration.